<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2965">
  <stage>Registered</stage>
  <submitdate>27/10/2010</submitdate>
  <approvaldate>27/10/2010</approvaldate>
  <nctid>NCT01230801</nctid>
  <trial_identification>
    <studytitle>Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease</studytitle>
    <scientifictitle>A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-023561-22</secondaryid>
    <secondaryid>POM-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pompe Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - BMN 701

Experimental: BMN 701 - IV infusion


Other interventions: BMN 701
GILT-tagged recombinant human GAA

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-BMN 701 antibody titer</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-Insulin-like-growth-factor antibody titer</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile of BMN 701</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean distance walked as measured by the Six-minute Walk Test (6MWT)</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Patient or patient's parent or legal guardian has provided written informed consent
             after the nature of the study has been explained, and prior to any study-related
             procedures;

          -  Patient has been diagnosed with Pompe Disease prior to or during the screening period
             based on 2 GAA gene mutations and either: endogenous GAA activity &lt;75% of the lower
             limit of the normal adult range reported by the testing laboratory, as assessed in
             cultured skin fibroblasts -or- endogenous GAA activity &lt;75% of the lower limit of the
             normal adult range reported by the testing laboratory, as assessed by dried blood spot
             or whole blood assay;

          -  Patient is male or female and 13 years of age or older at the time of enrollment in
             the study;

          -  Sexually active patients must be willing to use an acceptable method of contraception
             while participating in the study and for at least 30 days following the last dose of
             BMN 701;

          -  If patient is female and not considered to be of childbearing potential, she is at
             least 2 years post-menopausal or had tubal ligation at least 1 year prior to
             screening, or who have had total hysterectomy;

          -  If patient is female and of childbearing potential, she has negative urine pregnancy
             tests during the Screening Period and at the Baseline visit and be willing to have
             additional pregnancy tests during the study;

          -  Patient has =30% predicted upright FVC and either &lt;80% predicted upright FVC, or &gt;10%
             reduction in supine FVC compared to upright FVC during the Screening Period;

          -  Patient is na√Øve to Enzyme Replacement Therapy (ERT) with rhGAA;

          -  Patient must be able to ambulate at least 40 meters (131.2 feet) on the 6MWT conducted
             at the Screening visit (use of assistive devices such as walker, cane, or crutches, is
             permitted); and

          -  Patient has the ability to comply with the protocol requirements, in the opinion of
             the Investigator.</inclusivecriteria>
    <inclusiveminage>13</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Patient has a history of diabetes or other disease known to cause hypoglycemia and is
             currently receiving, or might anticipate receiving, hypoglycemic agents during the
             course of the study;

          -  Patient has been on any immunosuppressive medication other than glucocorticosteroids
             within 1 year prior to enrollment into this study;

          -  Patient requires invasive ventilatory assistance at the time of enrollment into the
             study;

          -  Patient has received any investigational medication within 30 days prior to the first
             dose of study drug or is scheduled to receive any investigational drug other than BMN
             701 during the course of the study;

          -  Patient has previously been admitted to the study;

          -  Patient is breastfeeding at screening or planning to become pregnant (self or partner)
             at any time during the study;

          -  Patient has a medical condition or extenuating circumstance that, in the opinion of
             the Investigator, might compromise the patient's ability to comply with the protocol
             requirements or compromise the patient's well being or safety;

          -  Patient has any condition that, in the view of the Investigator, places the patient at
             high risk of poor treatment compliance or of not completing the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioMarin Pharmaceutical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 1/2, open-label, multicenter, multiple dose escalation study of BMN 701 administered
      by intravenous infusion every 2 weeks over a 24-week treatment period to patients with
      late-onset Pompe disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01230801</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>William Lang, MD</name>
      <address>BioMarin Pharmaceutical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>